References
- Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569–74
- Kim DG, Hong SC, Kim HJ, Chi JG, Han MH, Choi KS, et al. Cerebral aspergillosis in immunologically competent patients. Surg Neurol 1993; 40: 326–31
- Colombo AL, Rosas RC. Successful treatment of an Aspergillus brain abscess with caspofungin: case report of a diabetic patient intolerant of amphotericin B. Eur J Clin Microbiol Infect Dis 2003; 22: 575–6
- Higashiyama Y, Kohno S. Micafungin: a therapeutic review. Expert Rev Anti Infect Ther 2004; 2: 345–55
- Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142–51
- Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006; 42: 1171–8
- Groll AH, Mickiene D, Petraitis V, Petraitiene R, Ibrahim KH, Piscitelli SC, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001; 45: 3322–7
- Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867–75
- Kishino S, Ohno K, Shimamura T, Furukawa H, Todo S. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant 2004; 18: 676–80
- Guinea J, Pelaez T, Alcala L, Ruiz-Serrano MJ, Bouza E. Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. Antimicrob Agents Chemother 2005; 49: 3495–7
- Nakai T, Uno J, Otomo K, Ikeda F, Tawara S, Goto T, et al. In vitro activity of FK463, a novel lipopeptide antifungal agent, against a variety of clinically important moulds. Chemotherapy 2002; 48: 78–81